<DOC>
	<DOC>NCT02236715</DOC>
	<brief_summary>Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice</brief_summary>
	<brief_title>Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Primarily patients of both gender, older than 30 years, who suffer from chronic obstructive airways disease Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® unit dose vial 500 µg</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>